Anti-CD19 CAR T-Cell Therapy in Children with Relapsed/Refractory ALL


Anti-CD19 CAR T-Cell Therapy in Children with Relapsed/Refractory ALL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with David L Porter, MD (3/3/14)
Lee DL et al. Anti-CD19 chimeric antigen receptor (CAR) T cells produce complete responses with acceptable toxicity but without chronic B-cell aplasia in children with relapsed or refractory acute lymphoblastic leukemia (ALL) even after allogeneic hematopoietic stem cell transplantation (HSCT). Proc ASH 2013;Abstract 68.

Dr Porter is Jodi Fisher Horowitz Professor of Leukemia Care Excellence and Director of Blood and Marrow Transplantation at the University of Pennsylvania Health System's Abramson Cancer Center in Philadelphia, Pennsylvania.